DETQ

DETQ is a selective, allosteric and orally active dopamine D1 receptor (Dopamine Receptor) potentiator. In HEK293 cells expressing the human D1 receptor, DETQ increases cAMP with an EC50 of 5.8 nM and a Kb of 26 nM. DETQ shows ~30-fold less potent at rat and mouse D1 receptors and is inactive at the human D5 receptor[1].

Product Specifications

CAS Number

[1638667-81-8]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/detq.html

Solubility

10 mM in DMSO

Smiles

C[C@@H]1N(C(CC2=C(Cl)C=CC=C2Cl)=O)[C@@H](CO)CC3=C1C=CC=C3C(C)(O)C

Molecular Formula

C22H25Cl2NO3

Molecular Weight

422.34

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362-P403+P233-P405-P501

References & Citations

[1]Kjell A Svensson, et al. An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis. J Pharmacol Exp Ther. 2017 Jan;360 (1) :117-128.|[2]Herbert Y Meltzer, et al. The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice. Behav Brain Res. 2019 Apr 1;361:139-150.